IDEX Corporation — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. IDEX operates across Fluid & Metering Technologies, Health & Science Technologies, and Fire & Safety/Diversified Products. Figures below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $489.4 | $427.1 | +15%; 6% organic growth, 10% acquisitions, 1% unfavorable currency |
| Gross profit / margin | $202.9 / 41.5% | $178.7 / 41.8% | Profit +14%; margin down 0.3 percentage points |
| Operating income / margin | $84.6 / 17.3% | $77.7 / 18.2% | Income +9%; margin down 0.9 points |
| Net income | $52.2 | $48.0 | +9% |
| Diluted EPS | $0.62 | $0.57 | +9% |
| Operating cash flow | $58.7 | $29.1 | +$29.6 |
Higher volume and productivity supported operating income. Margin pressure reflected product mix, acquisition dilution, and $4.9 million of restructuring charges. Interest expense rose to $10.7 million from $6.5 million, principally due to debt associated with the CVI MG acquisition and higher interest costs. The effective tax rate fell to 29.5% from 31.8%.
Segments
- Fluid & Metering Technologies: Sales $212.7 million, up 7%; organic growth 8%. Operating income $44.5 million; margin 20.9% versus 21.0%. Energy, Chemical/Food/Process, and Agriculture grew; municipal water demand remained weak.
- Health & Science Technologies: Sales $173.8 million, up 35%, including 33% from acquisitions; organic growth 2%. Operating income $30.3 million; margin 17.4% versus 22.8%, reflecting acquisition dilution and restructuring. Scientific instrumentation, defense, and semiconductor markets were areas of weakness.
- Fire & Safety/Diversified Products: Sales $104.1 million, up 5%; organic growth 7%. Operating income $23.7 million; margin 22.8% versus 21.4%, supported by volume and productivity.
Liquidity, cash flow, and debt
Cash was $245.5 million at March 31, up from $230.3 million at year-end. Working capital was $579.8 million and the current ratio was 3.3:1. Operating cash flow of $58.7 million funded $8.5 million of capital expenditures; investing cash use was $8.6 million. Financing cash use was $39.8 million, including $14.2 million of dividends, $10.2 million of share repurchases, and net debt repayments.
Total borrowings were $773.6 million, down from $808.8 million at December 31, 2011; long-term borrowings were $769.9 million. The company had $11.2 million drawn on its $700 million revolving facility and reported approximately $681.8 million of net available capacity. Leverage was 2.0:1 and interest coverage 11.8:1; IDEX reported compliance with applicable financial covenants. Approximately 2% of debt was floating-rate; management estimated a 50-basis-point rate move would change annual interest expense by about $0.1 million.
Outlook, risks, and notable items
- No specific full-year earnings or revenue guidance is provided in the supplied filing text. Management said cash and expected operating cash generation should be sufficient for operating needs, capital spending, debt interest, benefit-plan funding, authorized repurchases, and dividends through 2012 and 2013; further acquisitions could be debt-financed.
- Management cited exposure to industrial activity, end-market capital spending, foreign exchange, and successful integration and profitable operation of acquired businesses. Segment commentary noted municipal funding pressure, NIH funding concerns and customer inventory reductions, and defense and semiconductor market headwinds.
- The 2011 cost-reduction program produced $4.9 million of Q1 restructuring expense; initiatives included employee reductions and facility rationalization. The original program included severance benefits for 337 employees.
- After quarter-end, IDEX acquired Precision Photonics for approximately $20.5 million on April 11 and ERC for approximately $20.0 million on April 30; both join Health & Science Technologies.
- Asbestos-related lawsuits remain outstanding. The company said most resolved claims have been dismissed without payment or settled for insignificant amounts, historically with most settlement and legal costs covered by insurance; it cannot predict future insurance coverage and recorded no provision beyond ordinary-course deductibles. Other ordinary-course legal proceedings were not expected to have a material adverse effect.
- Management reported disclosure controls were effective as of March 31, 2012, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- How much reported sales growth and future performance depend on acquisitions versus organic growth, particularly in Health & Science Technologies.
- Whether segment margin pressure eases as restructuring actions take effect and acquisition integration progresses.
- Debt reduction, covenant headroom, and cash generation relative to acquisition spending, dividends, and repurchases.
- Performance in weaker end markets, including municipal water, scientific instrumentation, defense, and semiconductors.
- Integration and purchase accounting for the April acquisitions, and potential exposure if asbestos-related insurance coverage changes.